CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
NSABP B-41 中早期 HER2 阳性乳腺癌 TIL（肿瘤浸润淋巴细胞）的 AI 驱动评估与人工评估
英文原题：AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
查看英文原题
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
联合评估TIL（肿瘤浸润淋巴细胞）和基因表达特征（GES），有望指导乳腺癌个体化治疗。本研究纳入 III 期 NSABP B-41 试验中的 262 名患者；该试验评估新辅助 HER2 靶向治疗与化疗联用。研究采用人工和人工智能（AI）方法分析 TIL，并根据 RNA 测序分析 GES。在雌激素受体（ER）阴性患者中，作为连续变量的人工 TIL 较高与病理完全缓解（pCR）相关。无论 ER 状态如何，AI 评估的 TIL 均与 pCR 相关。免疫基因表达特征（iGES）也与 pCR 相关。人工 TIL 与无事件生存期（EFS）无关联，而 AI-TIL 显示边缘性关联。研究结果支持将 TIL 评估与 GES 结合，用作 HER2 阳性乳腺癌的预后生物标志物。未来需研究其预测价值，以指导治疗决策。
展开英文摘要原文
The assessment of tumor-infiltrating lymphocyte (TILs), together with gene expression signatures (GES), has the potential to guide personalized breast cancer therapy.
We included 262 patients from the phase III NSABP B-41 trial, which evaluated neoadjuvant HER2-targeted therapies in combination with chemotherapy.
We conducted a manual and artificial intelligence (AI)-based analyses of TILs, as well as GES from RNA sequencing. Higher manual TILs as a continuous variable were associated with pathologic complete response (pCR) in patients with estrogen receptor (ER)-negative disease. AI-based TILs were associated with pCR regardless of ER status.
Immune GES (iGES) were associated with pCR. Manual TILs were not associated with event-free survival (EFS), while AI-TIL showed a marginal association. These results support the use of TIL assessment, complemented by GES, as a prognostic biomarker in HER2-positive breast cancer. Future studies are needed to evaluate their predictive utility to guide treatment decisions.
论文信息
- 作者
- Schlam I、Tang G、AbdulJabbar K、Yan H、Gu X、Freeman TJ、Maley S、Harris BT
- 第一作者单位
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.United States
- 通讯作者单位
- Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. sms248@georgetown.edu.United States
- 期刊
- NPJ breast cancer2026 May 14
- 原文标识
- PubMed 42135347 · DOI 10.1038/s41523-026-00961-w